| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer M De Laurentiis, G Arpino, E Massarelli, A Ruggiero, C Carlomagno, ... Clinical cancer research 11 (13), 4741-4748, 2005 | 427 | 2005 |
| Final overall survival: fulvestrant 500mg vs 250mg in the randomized CONFIRM trial AD Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ... Journal of the National Cancer Institute 106 (1), djt337, 2014 | 356 | 2014 |
| Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ... Breast cancer research and treatment 136, 795-804, 2012 | 263 | 2012 |
| Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients M Pestrin, F Salvianti, F Galardi, F De Luca, N Turner, L Malorni, ... Molecular oncology 9 (4), 749-757, 2015 | 189 | 2015 |
| Challenges in the management of advanced, ER-positive, HER2-negative breast cancer CD Hart, I Migliaccio, L Malorni, C Guarducci, L Biganzoli, A Di Leo Nature reviews Clinical oncology 12 (9), 541-552, 2015 | 167 | 2015 |
| Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts CJ Creighton, S Massarweh, S Huang, A Tsimelzon, SG Hilsenbeck, ... Cancer research 68 (18), 7493-7501, 2008 | 167 | 2008 |
| Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice A McCartney, I Migliaccio, M Bonechi, C Biagioni, D Romagnoli, ... Frontiers in oncology 9, 666, 2019 | 164 | 2019 |
| A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients … L Malorni, S Piazza, Y Ciani, C Guarducci, M Bonechi, C Biagioni, ... Oncotarget 7 (42), 68012, 2016 | 134 | 2016 |
| Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer C Guarducci, M Bonechi, M Benelli, C Biagioni, G Boccalini, D Romagnoli, ... NPJ Breast Cancer 4 (1), 38, 2018 | 105 | 2018 |
| Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast … L Malorni, G Curigliano, AM Minisini, S Cinieri, CA Tondini, K D’Hollander, ... Annals of Oncology 29 (8), 1748-1754, 2018 | 101 | 2018 |
| Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response C Guarducci, M Bonechi, G Boccalini, M Benelli, E Risi, A Di Leo, ... Breast Care 12 (5), 304-308, 2017 | 80 | 2017 |
| Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology M De Laurentiis, G Cancello, L Zinno, E Montagna, L Malorni, A Esposito, ... Annals of Oncology 16, iv7-iv13, 2005 | 79 | 2005 |
| Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, R Pereira, J Veeraraghavan, ... Clinical Cancer Research 27 (17), 4870-4882, 2021 | 74 | 2021 |
| The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy I De Santo, A McCartney, I Migliaccio, A Di Leo, L Malorni Cancers 11 (12), 1894, 2019 | 70 | 2019 |
| New approaches for improving outcomes in breast cancer in Europe A Di Leo, G Curigliano, V Diéras, L Malorni, C Sotiriou, C Swanton, ... The Breast 24 (4), 321-330, 2015 | 70 | 2015 |
| Cell-free DNA-methylation-based methods and applications in oncology F Galardi, F De Luca, D Romagnoli, C Biagioni, E Moretti, L Biganzoli, ... Biomolecules 10 (12), 1677, 2020 | 54 | 2020 |
| Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes MD Castellone, AM Cirafici, GD Vita, VD Falco, L Malorni, G Tallini, ... Oncogene 22 (2), 246-255, 2003 | 54 | 2003 |
| Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial A McCartney, M Bonechi, F De Luca, C Biagioni, G Curigliano, E Moretti, ... Clinical Cancer Research 26 (9), 2131-2139, 2020 | 49 | 2020 |
| Blockade of AP-1 potentiates endocrine therapy and overcomes resistance L Malorni, M Giuliano, I Migliaccio, T Wang, CJ Creighton, M Lupien, X Fu, ... Molecular Cancer Research 14 (5), 470-481, 2016 | 46 | 2016 |
| Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis M Barba, L Yang, HJ Schünemann, F Sperati, S Grioni, S Stranges, ... Journal of Experimental & Clinical Cancer Research 28, 1-8, 2009 | 42 | 2009 |
Angelo Di LeoHospital of PratoVerifierad e-postadress på uslcentro.toscana.it